Bach JR, Baird JS, Plosky D, Navado J, Weaver B. Spinal muscular atrophy type 1: management and outcomes. Pediatr Pulmonol. 2002;34(1):16–22.
Borkowska J, Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Zerres K. Early infantile form of spinal muscular atrophy (werdnig-hoffmann disease) with prolonged survival. Folia Neuropathol. 2002;40(1):19–26.
Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004;114(5):e548–53.
Milligan JN, Blasco-Perez L, Costa-Roger M, Codina-Sola M, Tizzano EF. Recommendations for interpreting and reporting silent carrier and disease-modifying variants in SMAtesting workflows. Genes (Basel). 2022;13(9):1657.
Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: Mutations, testing, and clinical relevance. Appl Clin Genet. 2021;14:11–25.
Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet. 2020;21:231–61.
Chaytow H, Huang YT, Gillingwater TH, Faller KME. The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci. 2018;75(21):3877–94.
Singh RN, Howell MD, Ottesen EW, Singh NN. Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech. 2017;1860(3):299–315.
Coovert DD, Le TT, McAndrew PE, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6(8):1205–14.
Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883–91.
Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518–23.
Piepers S, van den Berg LH, Brugman F, et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol. 2008;255(9):1400–4.
Annoussamy M, Seferian AM, Daron A, et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NATHIS-SMA study. Ann Clin Transl Neurol. 2021;8(2):359–73.
Cances C, Vlodavets D, Comi GP, et al. Natural history of type 1 spinal muscular atrophy: A retrospective, global, multicenter study. Orphanet J Rare Dis. 2022;17(1):300.
Mercuri E, Lucibello S, Perulli M, et al. Longitudinal natural history of type I spinal muscular atrophy: A critical review. Orphanet J Rare Dis. 2020;15(1):84.
Veldhoen ES, Wijngaarde CA, Hulzebos EHJ, et al. Natural history of respiratory muscle strength in spinal muscular atrophy: A prospective National cohort study. Orphanet J Rare Dis. 2022;17(1):70.
Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810–7.
Kaufmann P, McDermott MP, Darras BT, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68(6):779–86.
Pane M, Palermo C, Messina S, et al. An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology. 2018;91(8):e696–703.
Tizzano EF. Treating neonatal spinal muscular atrophy: A 21st century success story? Early Hum Dev. 2019;138:104851.
Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021;64(2):153–5.
Motyl AAL, Gillingwater TH. Timing is everything: clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy. Cell Rep Med. 2022;3(8):100725.
Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag. 2019;15:1153–61.
Ricci M, Cicala G, Capasso A, et al. Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable? Ann Neurol. 2023;94(6):1126–35.
Souza PVS, Pinto W, Ricarte A, et al. Clinical and radiological profile of patients with spinal muscular atrophy type 4. Eur J Neurol. 2021;28(2):609–19.
Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7(2):97–100.
Lusakowska A, Jedrzejowska M, Kaminska A, et al. Observation of the natural course of type 3 spinal muscular atrophy: data from the Polish registry of spinal muscular atrophy. Orphanet J Rare Dis. 2021;16(1):150.
Wadman RI, Wijngaarde CA, Stam M, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. Eur J Neurol. 2018;25(3):512–8.
Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110(4):301–7.
Wadman RI, Stam M, Gijzen M, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4. J Neurol Neurosurg Psychiatry. 2017;88(4):365–7.
Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22(8):946–51.
Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy – new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1–13.
Spinraza prescribing information. Cambridge: Biogen. 2016. Available from: https://www.spinraza.com/content/dam/commercial/spinraza/caregiver/en_us/pdf/spinraza-prescribing-information.pdf
Zolgensma prescribing information. Bannockburn: AveXis Inc. 2019. Available from: https://www.novartis.com/us-en/sites/novartis_us/files/zolgensma.pdf
Evrysdi prescribing information. San Francisco: Genentech. 2020. Available from: https://www.gene.com/download/pdf/evrysdi_prescribing.pdf
Finkel RS, Ryan MM, Pascual Pascual SI, et al. Scientific rationale for a higher dose of Nusinersen. Ann Clin Transl Neurol. 2022;9(6):819–29.
Hagenacker T, Wurster CD, Günther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317–25.
Osmanovic A, Schreiber-Katz O, Petri S. Nusinersen wearing-off in adult 5q-spinal muscular atrophy patients. Brain Sci. 2021;11(3):367.
Cure SMA, SMA Drug Pipeline. 2024. Available from: https://www.curesma.org/sma-drug-pipeline/
Proud CM, Mercuri E, Finkel RS, et al. Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification. Ann Clin Transl Neurol. 2023;10(11):2155–60.
Harada Y, Rao VK, Arya K, et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020;62(4):550–4.
Jha NN, Kim JK, Her YR, Monani UR. Muscle: an independent contributor to the neuromuscular spinal muscular atrophy disease phenotype. JCI Insight. 2023;8(18):e171878.
United States Food and Drug Administration. Focus area: Patient-reported outcomes and other clinical outcome assessments. 2022. Available from: https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments
Slayter J, Hodgkinson V, Lounsberry J, et al. A Canadian adult spinal muscular atrophy outcome measures toolkit: results of a National consensus using a modified Delphi method. J Neuromuscul Dis. 2021;8(4):579–88.
Slayter J, Casey L, O’Connell C. Patient reported outcome measures in adult spinal muscular atrophy: A scoping review and graphical visualization of the evidence. J Neuromuscul Dis. 2023;10(2):239–50.
Belter L, Peterson I, Jarecki J. Evaluating perceived fatigue within an adult spinal muscular atrophy population. Neurol Ther. 2023; 12(6):2161-2175.
Binz C, Schreiber-Katz O, Kumpe M, et al. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving Nusinersen treatment. J Neurol. 2021;268(3):950–62.
Dunaway Young S, Montes J, Kramer SS, Podwika B, Rao AK, De Vivo DC. Perceived fatigue in spinal muscular atrophy: A pilot study. J Neuromuscul Dis. 2019;6(1):109–17.
Osmanovic A, Ranxha G, Kumpe M, et al. Treatment expectations and patient-reported outcomes of Nusinersen therapy in adult spinal muscular atrophy. J Neurol. 2020;267(8):2398–407.
Crisafulli O, Berardinelli A, D’Antona G. Fatigue in spinal muscular atrophy: A fundamental open issue. Acta Myol. 2024;43(1):1–7.
Rodriguez-Torres RS, Uher D, Gay EL et al. Measuring fatigue and fatigability in spinal muscular atrophy (SMA): challenges and opportunities. J Clin Med. 2023;12(10):3458.
Stolte B, Neuhoff S, Lipka J et al. Performance fatigability in adults with spinal muscular atrophy treated long-term with Nusinersen. Muscle Nerve. 2024;70(6):1223-1229.
Rodriguez-Torres R, Kanner CH, Gay EL, et al. Development of the SMA EFFORT: A new approach to characterize perceived physical fatigability in spinal muscular atrophy. J Neuromuscul Dis. 2025;12(1):22143602241313326.
Werlauff U, Højberg A, Firla-Holme R, Steffensen BF, Vissing J. Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale. Qual Life Research: Int J Qual Life Aspects Treat Care Rehabilitation. 2014;23(5):1479–88.
Binz C, Osmanovic A, Thomas NH, et al. Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9(3):351–62.
Zizzi CE, Luebbe E, Mongiovi P, et al. The spinal muscular atrophy health index: A novel outcome for measuring how a patient feels and functions. Muscle Nerve. 2021;63(6):837–44.
Domine MC, de Lemus M, Castellano IP, Ñungo-Garzón NC, Sevilla-Mantecón T, Vázquez-Costa JF. Physical fatigue and perceived fatigability in adolescents and adults with spinal muscular atrophy: A pilot study. Neurol Perspect. 2022;2(4):199–208.
Vázquez-Costa JF, Branas-Pampillón M, Medina-Cantillo J, et al. Validation of a set of instruments to assess patient- and caregiver-oriented measurements in spinal muscular atrophy: results of the SMA-TOOL study. Neurol Ther. 2023;12(1):89–105.
Belter L, Peterson I, Jarecki J. Evaluating perceived fatigue within an adult spinal muscular atrophy population. Neurol Ther. 2023;12(6):2161–75.
Belter L, Whitmire S, Welsh E, Schroth M. State of SMA: 2023 Report. 2024 May 6, 2024.
Benning L, Das-Gupta Z, Sousa Fialho L, Wissig S, Tapela N, Gaunt S. Balancing adaptability and standardisation: insights from 27 routinely implemented ICHOM standard sets. BMC Health Serv Res. 2022;22(1):1424.
Cure SMA. 2024. Available from: https://www.curesma.org/
Belter L, Cook SF, Crawford TO, et al. An overview of the cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members. J Neuromuscul Dis. 2018;5(2):167–76.
Lapp HS, Freigang M, Hagenacker T, Weiler M, Wurster CD, Günther R. Biomarkers in 5q-associated spinal muscular atrophy: A narrative review. J Neurol. 2023;270(9):4157–78.
Glascock J, Darras BT, Crawford TO, et al. Identifying biomarkers of spinal muscular atrophy for further development. J Neuromuscul Dis. 2023;10(5):937–54.
Gavriilaki M, Papaliagkas V, Stamperna A, et al. Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: A systematic review. Acta Neurol Belgica. 2023;123(5):1735–45.
Burk MFM, Professions RMUH. A new functional scale for spinal muscular atrophy: development and validation of the functional ability scale for evolving SMA (EVOLVE-SMA) 2024.
Yeo CJJ, Tizzano EF, Darras BT. Challenges and opportunities in spinal muscular atrophy therapeutics. Lancet Neurol. 2024;23(2):205–18.
Rebollo P, García-López S, Povedano M, et al. Design and validation of a clinical outcome measure for adolescents and adult patients with spinal muscular atrophy: SMA life study protocol. Neurol Ther. 2024;13(1):233–49.
Kessler T, Sam G, Wick W, Weiler M. Evaluation of Risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures. Eur J Neurol. 2024;31(1):e16099.
Coratti G, Bovis F, Pera MC et al. Determining minimal clinically important differences in the Hammersmith functional motor scale expanded for untreated spinal muscular atrophy patients: an international study. Eur J Neurol. 2024;31:e16309.
Querin G, Lenglet T, Debs R, et al. Development of new outcome measures for adult SMA type III and IV: A multimodal longitudinal study. J Neurol. 2021;268(5):1792–802.
Konersman CG, Ewing E, Yaszay B, Naheedy J, Murphy S, Skalsky A. Nusinersen treatment of older children and adults with spinal muscular atrophy. Neuromuscul Disord. 2021;31(3):183–93.
Krosschell KJ, Brown L, Hoffman K, et al. Longitudinal assessment of timed function tests in ambulatory individuals with SMA treated with Nusinersen. J Neuromuscul Dis. 2023;10(3):337–48.
Krosschell KJ, Townsend EL, Kiefer M, et al. Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal analysis. Neuromuscul Disord. 2022;32(2):125–34.
Oskoui M, Day JW, Deconinck N, et al. Two-year efficacy and safety of Risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270(5):2531–46.
Perumal TM, Wolf D, Berchtold D, et al. Digital measures of respiratory and upper limb function in spinal muscular atrophy: Design, feasibility, reliability, and preliminary validity of a smartphone sensor-based assessment suite. Neuromuscul Disord. 2023;33(11):845–55.
Veerapandiyan A, Eichinger K, Guntrum D, et al. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience. Muscle Nerve. 2020;61(2):222–6.
Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ. Prospective cohort study of Nusinersen treatment in adults with spinal muscular atrophy. J Neuromuscul Dis. 2020;7(3):257–68.
Zang J, Weiss D, Dumitrascu C, et al. Maximal mouth opening in infants and toddlers with spinal muscular atrophy: A prospective controlled study. Orphanet J Rare Dis. 2025;20(1):24.
Berardi A, Conte A, Cimmino L, et al. Evaluation of the psychometric properties of the health assessment questionnaire (HAQ) in a population of individuals with multiple sclerosis. Front Neurol. 2022;13:847786.
The ALS CNTF treatment study (ACTS) phase I-II study group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996;53(2):141–7.
Peng S, Meng L, Fang R, et al. Current state of research on exercise for the treatment of myasthenia gravis: A scoping review. Complement Ther Med. 2024;81:103033.
Trundell D, Skalicky A, Staunton H, et al. Development of the SMA independence scale-upper limb module (smais-ulm): A novel scale for individuals with type 2 and non-ambulant type 3 SMA. J Neurol Sci. 2022;432:120059.
Lefton-Greif MA, Belter L, Jarecki J et al. Patient-reported assessment of bulbar function in spinal muscular atrophy (SMA): validation of a self-report scale. J Neuromuscul Dis. 2025;12:22143602251325741.
Rich KA, Fox A, Yalvac M, et al. Neurofilament levels in CSF and serum in an adult SMA cohort treated with Nusinersen. J Neuromuscul Dis. 2022;9(1):111–9.
Andrés-Benito P, Vázquez-Costa JF, Ñungo Garzón NC et al. Neurodegeneration biomarkers in adult spinal muscular atrophy (SMA) patients treated with Nusinersen. Int J Mol Sci. 2024;25(7):3810.
Gavriilaki M, Moschou M, Papaliagkas V, et al. Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: A systematic review and meta-analysis. Neuromuscul Disord. 2022;32(3):185–94.
Montes J, McDermott MP, Martens WB, et al. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74(10):833–8.
Montes J, Goodwin AM, McDermott MP, et al. Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8(5):1086–95.
Montes J, Glanzman AM, Mazzone ES, et al. Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy. Muscle Nerve. 2015;52(6):942–7.
Montes J, McDermott MP, Mirek E, et al. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. PLoS ONE. 2018;13(6):e0199657.
Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54(5):836–42.
Pechmann A, Behrens M, Dörnbrack K, et al. Improvements in walking distance during Nusinersen treatment – a prospective 3-year smartcare registry study. J Neuromuscul Dis. 2023;10(1):29–40.
Kizina K, Stolte B, Totzeck A, et al. Fatigue in adults with spinal muscular atrophy under treatment with Nusinersen. Sci Rep. 2020;10(1):11069.
Montes J, Dunaway Young S, Mazzone ES, et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve. 2019;60(4):409–14.
Stolte B, Neuhoff S, Lipka J, et al. Performance fatigability in adults with spinal muscular atrophy treated long-term with Nusinersen. Muscle Nerve. 2024;70(6):1223–9.
Habets LE, Bartels B, Jeneson JAL, et al. Enhanced low-threshold motor unit capacity during endurance tasks in patients with spinal muscular atrophy using pyridostigmine. Clin Neurophysiology: Official J Int Federation Clin Neurophysiol. 2023;154:100–6.
Habets LE, Bartels B, de Groot JF, et al. Motor unit reserve capacity in spinal muscular atrophy during fatiguing endurance performance. Clin Neurophysiology: Official J Int Federation Clin Neurophysiol. 2021;132(3):800–7.
Bartels B, de Groot JF, Habets LE, et al. Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet J Rare Dis. 2020;15(1):75.
Yoon JA, Jeong Y, Lee J, Lee DJ, Lee KN, Shin YB. Improvement in functional motor scores in patients with non-ambulatory spinal muscle atrophy during Nusinersen treatment in South korea: A single center study. BMC Neurol. 2024;24(1):210.
Tang WJ, Gu B, Montalvo S et al. Assessing the assisted six-minute cycling test as a measure of endurance in non-ambulatory patients with spinal muscular atrophy (SMA). J Clin Med. 2023;12(24):7582.
Duong T, Wolford C, McDermott MP, et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;11(3):e317–27.
Bartels B, de Groot JF, Habets LE, et al. Correlates of fatigability in patients with spinal muscular atrophy. Neurology. 2021;96(6):e845–52.
Walter MC, Wenninger S, Thiele S, et al. Safety and treatment effects of Nusinersen in longstanding adult 5q-SMA type 3 – a prospective observational study. J Neuromuscul Dis. 2019;6(4):453–65.
Mattsson M, Möller B, Lundberg I, Gard G, Boström C. Reliability and validity of the fatigue severity scale in Swedish for patients with systemic lupus erythematosus. Scand J Rheumatol. 2008;37(4):269–77.
Mazzella A, Cruz R, Belter L et al. Assessing perspectives of disease burden and clinically meaningful changes using the spinal muscular atrophy health index in adolescents and young adults. Muscle Nerve. 2022;66(3):276-281.